UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~March 3111, ~~2013~~2014

PATIENT SAFETY TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE		001-09727		13-3419202
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15440 LAGUNA CANYON ROAD, SUITE 150 , IRVINE, CALIFORNIA 92618

(Address of Principal Executive Offices) (Zip Code)

(949) 387-2277

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see ~~General~~ Gel Instruction A.2. below):

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 18.01 ~~Entry~~Other ~~into a Material Definitive Agreement~~Events.

~~Merger~~On ~~Agreement~~February 25, 2014, Patient Safety Technologies, Inc. (“Patient Safety” or the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Definitive Proxy Statement”) with respect to the special meeting of Patient Safety stockholders scheduled to be held on March 21, 2014 (the “Special Meeting”) to, among other things, vote on the approval of the merger (the “Merger”) with Stryker Corporation (“Stryker”).

OnAs ~~December~~previously 31disclosed in the Definitive Proxy Statement, ~~2013~~three putative stockholders of Patient Safety filed putative class actions on behalf of an alleged class of Patient Safety stockholders in the Superior Court of California, ~~Stryker~~County ~~Corporation~~of Orange, aunder ~~Michigan~~the ~~corporation~~following ~~(“Stryker”),~~captions: PSHofman ~~Merger~~v. ~~Sub~~Patient Safety Technologies, Inc., aet ~~Delaware~~al., ~~corporation~~Case ~~and~~No. a30-2014-00698513-CU-SL-CXC, ~~wholly~~Martinsen ~~owned~~v. ~~subsidiary~~Patient ofSafety ~~Stryker~~Technologies, ~~(“Purchaser”)~~Inc., et al., Case No. 30-2014-00701480-CU-SL-CXC, and Haas v. Patient Safety Technologies, Inc., et al., Case No. 30-2014-00705803-CU-SL-CXC, (together, the “~~Company~~California Actions”). Plaintiff ~~entered~~Hofman ~~into~~filed an ~~Agreement~~amended ~~and~~complaint ~~Plan~~on ofJanuary ~~Merger~~29, 2014 (the “~~Merger~~Amended ~~Agreement~~Complaint”). On ~~pursuant~~February to25, ~~which~~2014, ~~subject~~Plaintiff toDonald Gregor filed a class action lawsuit in the ~~satisfaction~~Court orof ~~waiver~~Chancery of ~~certain~~the ~~conditions,~~State ~~Purchaser~~of ~~will~~Delaware ~~merge~~entitled ~~with~~Gregor ~~and~~v. ~~into~~Patient ~~the~~Safety ~~Company~~Technologies, ~~with~~Inc., ~~the~~et ~~separate~~al., ~~corporate~~Case ~~existence~~No. of9395-VCP ~~Purchaser~~(the ~~thereupon~~“Delaware ~~ceasing~~Action,” and, together with the ~~Company~~California ~~being~~Actions, the ~~surviving~~“Actions”). Plaintiffs ~~corporation~~challenge the proposed acquisition of the ~~Merger~~Company ~~and~~by aStryker ~~wholly~~and ~~owned~~disclosures ~~subsidiary~~made ofin ~~Stryker (~~the ~~“Merger”)~~Definitive Proxy Statement.

AtOn ~~the~~March ~~effective~~11, ~~time~~2014, of the ~~Merger,~~parties ~~each~~to ~~issued~~the ~~and~~Actions ~~outstanding~~reached ~~common~~an ~~share~~agreement ~~(other~~in ~~than~~principle ~~common~~providing ~~shares~~for ~~held by~~ the ~~Company,~~settlement ~~Stryker, Purchaser or a stockholder who properly demands appraisal~~ of ~~such~~the ~~common~~action ~~shares~~on ~~under~~the ~~Delaware~~terms ~~law)~~and ~~will~~conditions beset ~~converted~~forth ~~into~~in a ~~right~~memorandum toof ~~receive~~understanding ~~in cash $2.22 per common share~~ (the “~~Common Consideration~~MOU”). ~~Each~~Pursuant ~~issued~~to ~~and outstanding share of Series A Preferred Stock (other than those shares held by~~ the ~~Company~~MOU, ~~Stryker,~~the ~~Purchaser~~defendants oragreed ~~a stockholder who properly demands appraisal of such common shares under Delaware law) will be converted into a right~~ to ~~receive~~make incertain ~~cash~~supplemental ~~$100.00 per share of Series A Preferred Stock. Further, each issued~~ and ~~outstanding~~amended ~~share~~disclosures ofto ~~Series B Preferred Stock (other than those shares held by~~ the ~~Company,~~disclosures ~~Stryker, Purchaser or a stockholder who properly demands appraisal of such common shares under Delaware law) will be converted into a right to receive~~ in ~~cash~~the ~~$296.00~~Definitive ~~per~~Proxy ~~share of Series B Preferred Stock~~Statement.

~~Each~~The ~~vested~~MOU ~~and~~further ~~exercisable~~provides ~~option to acquire common shares~~ that, isamong ~~outstanding~~other ~~immediately~~things, ~~prior~~(1) to the ~~Merger~~parties will beenter ~~canceled~~into ~~and~~a ~~terminated~~definitive instipulation ~~exchange~~of ~~for~~settlement (the ~~right~~“Stipulation”) toand ~~receive~~will asubmit ~~payment~~the inStipulation ~~cash equal~~ to the ~~product~~California ofcourt for review and approval; (a2) the ~~total~~Stipulation ~~number~~will ofprovide ~~common shares~~ for ~~which~~dismissal ~~such~~of ~~option~~the ~~remains~~ outstanding ~~and~~litigation ~~unexercised~~in ~~prior~~California ~~to the effective time~~ and ~~(b)~~Delaware on the ~~excess~~merits; (~~if any~~3) of the ~~Common~~Stipulation ~~Consideration~~will ~~over~~include ~~the~~a ~~exercise~~general ~~price~~release of ~~such~~defendants ~~option.~~of ~~All~~all ~~unvested~~claims ~~options~~relating ~~will~~to ~~become immediately vested and exercisable. Each of~~ the ~~Company,~~proposed ~~Purchaser~~Merger and ~~Stryker~~related ~~made~~transactions; ~~customary representations, warranties~~ and ~~covenants~~(4) in the ~~Merger~~proposed ~~Agreement,~~settlement ~~including,~~is ~~among~~conditioned ~~others~~on, ~~covenants~~among byother ~~the~~things, ~~Company~~class tocertification ~~conduct~~and ~~its~~final ~~business~~approval inby the ~~ordinary~~California ~~course~~court ~~during~~after ~~the~~notice ~~interim~~to ~~period~~Patient ~~between~~Safety’s ~~the execution of the Merger Agreement and the consummation of the Merger~~shareholders.

The ~~consummation~~settlement ofwill ~~the~~not ~~Merger~~affect ~~is subject to customary closing conditions, including, among others,~~ the ~~approval~~timing ~~by the Company’s stockholders, the absence~~ of ~~certain legal impediments to~~ the ~~consummation~~Special ofMeeting ~~the Merger, the receipt of specified governmental consents and approvals, the early termination~~ or ~~expiration of~~ the ~~waiting~~amount ~~period under the Hart Scott Rodino Antitrust Improvements Act~~ of ~~1976,~~merger asconsideration ~~amended~~to ~~(the~~be ~~“HSR~~paid ~~Act”), and, subject~~ to ~~materiality~~Patient ~~exceptions,~~Safety’s ~~the~~stockholders ~~accuracy~~in ofconnection ~~representations and warranties made by the Company and Stryker, respectively, and compliance by the Company and Stryker~~ with ~~their respective obligations under~~ the ~~Merger~~proposed ~~Agreement. The~~ Merger ~~is not subject to any financing condition~~.

Pursuant to the proposed settlement, Patient Safety has also agreed to make the amended and supplemental disclosures set forth below to the disclosures in the Definitive Proxy Statement. Important information concerning the proposed Merger is set forth in the Definitive Proxy Statement. The Definitive Proxy Statement is amended and supplemented by, and should be read as part of, and in conjunction with, the information set forth in this Current Report on Form 8-K. Capitalized terms used in this Current Report on Form 8-K but not otherwise defined herein have the meanings ascribed to those terms in the Definitive Proxy Statement.

The Company and the other defendants have vigorously denied, and continue vigorously to deny, that they have committed or aided and abetted in the commission of any violation of law or duties or engaged in any of the wrongful acts that were or could have been alleged in the referenced lawsuits, and expressly maintain that, to the extent applicable, they diligently and scrupulously complied with any applicable fiduciary and other legal duties and are entering into the contemplated settlement solely to eliminate the burden and expense of further litigation, to put the claims that were or could have been asserted to rest, and to avoid any possible delay to the closing of the Merger that might arise from further litigation. Nothing in this Current Report on Form 8-K, the MOU or any stipulation of settlement (including the Stipulation) shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth herein.

~~The~~AMENDED ~~Merger~~AND ~~Agreement~~SUPPLEMENTAL requires the necessary Company stockholder approval and, subject to certain exceptions, the Company has agreed (i) not to solicit alternative transactions or enter into discussions concerning, or provide confidential information in connection with, any alternative transaction and (ii) that the Company’s board of directors will recommend that the Company’s stockholders adopt the Merger Agreement.DISCLOSURE

~~Prior~~In the toproposed ~~adoption~~settlement of the ~~Merger~~aforementioned ~~Agreement~~lawsuits bydescribed ~~the~~in ~~Company’s~~this ~~stockholders,~~Current ~~the~~Report ~~Company’s~~on ~~board~~Form of8-K, ~~directors~~Patient ~~may~~Safety inmakes ~~certain~~the ~~circumstances~~following ~~change~~amended ~~its~~and ~~recommendation~~supplemental ~~that~~disclosures ~~the~~to ~~Company’s stockholders adopt~~ the ~~Merger~~Definitive ~~Agreement,~~Proxy ~~subject~~Statement. Without toadmitting ~~complying~~in ~~with~~any ~~certain~~way ~~notice~~that ~~and~~the ~~other~~disclosures ~~specified~~below ~~conditions~~are ~~set~~material ~~forth~~or inotherwise ~~the~~required ~~Merger~~by ~~Agreement~~law, ~~including~~Patient ~~giving~~Safety ~~Stryker~~makes the ~~opportunity~~following toamended ~~propose~~and ~~changes~~supplemental ~~to the Merger Agreement.~~disclosures:

The ~~Merger~~section ~~Agreement may be terminated under certain circumstances, including by the Company, prior to the adoption~~ of the ~~Merger~~Definitive ~~Agreement~~Proxy byStatement ~~the~~entitled ~~Company’s~~“The ~~stockholders, in the event that the Company receives an unsolicited proposal that the Company concludes, after following certain procedures, is a Superior Proposal (as defined in the~~ Merger—Background Agreement). If the Company receives a Superior Proposal, Stryker must be given the opportunity to match the Superior Proposal. In addition, Stryker may terminate the Merger Agreement under certain circumstances, including if the Company’s board of ~~directors changes its recommendation that stockholders adopt~~ the Merger” ~~Agreement~~is oramended ~~approves~~and asupplemented ~~Superior~~as ~~Proposal for an alternative transaction. In the foregoing circumstances, the Company would be required to pay Stryker a termination fee of $4 million.~~follows:

The ~~foregoing~~following ~~description~~disclosure ofsupplements the ~~Merger~~disclosure ~~Agreement~~on ~~does~~page ~~not~~22 ~~purport to be complete, and is qualified in its entirety by reference to the full text~~ of the ~~Merger~~Definitive ~~Agreement,~~Proxy ~~which~~Statement ~~is attached hereto as Exhibit 2.1 and is incorporated herein~~ by ~~reference. A~~adding copy of the Merger Agreement has been included to provide stockholders with information regarding its terms and is not intended to provide any factual information about the Company, Stryker or Purchaser. The representations, warranties and covenants contained in the Merger Agreement have been made solely for the purposes of the Merger Agreement and as of specific dates; were solely for the benefit of parties to the Merger Agreement; and are not intended as statements of fact to be relied upon by the Company’s stockholders, but rather as a ~~way~~new ofsentence ~~allocating~~after the ~~risk~~last ~~between~~sentence the parties in the event the statements therein prove to be inaccurate; have been modified or qualified by certain confidential disclosures that were made between the parties in connection with the negotiation of the ~~Merger~~eleventh ~~Agreement,~~paragraph which disclosures are not reflected in the Merger Agreement itself; may no longer be true as of a given date; and may apply standards of materiality in a way that is different from what may be viewed as material by stockholders. Accordingly, stockholders should not rely on ~~the~~such representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company, Stryker or Purchaser. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. The Company acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this Form 8-K not misleading.page:

Neither of the potential partners expressed interest in pursuing a transaction at that time.

The following disclosure supplements the disclosure on page 22 of the Definitive Proxy Statement by replacing the word “Following” with a new clause in the first sentence of the thirteenth paragraph on such page and by replacing the clause “Cardinal Health, Inc. (“Cardinal”)” in the first sentence of the Definitive Proxy with “Cardinal”:

As required by the terms of Patient Safety’s supply and distribution agreement with Cardinal Health, Inc. (“Cardinal”), following

The following disclosure supplements the disclosure on page 22 of the Definitive Proxy Statement by adding a new sentence after the last sentence of the thirteenth paragraph on such page:

Cardinal indicated that it valued Patient Safety below Patient Safety’s market capitalization and as a result did not intend to make an offer for Patient Safety or otherwise pursue an acquisition.

The following disclosure supplements the disclosure on page 22 of the Definitive Proxy Statement by adding a new clause immediately following the clause “Over the following week,” in the first sentence of the fourteenth paragraph on such page:

because the Patient Safety board was unable to find a mutually acceptable time to collectively assemble,

~~Voting~~The ~~Agreements~~following ~~Relating~~disclosure tosupplements ~~Merger~~the disclosure on page 23 of the Definitive Proxy Statement by adding a new clause immediately before the first sentence of the second paragraph on such page:

OnFollowing ~~December~~discussions ~~31, 2013, the Company entered into voting agreements (the “Voting Agreements”)~~ with ~~certain~~multiple ~~shareholders~~financial ofadvisors ~~the Company, namely, John P. Francis, Louis Glazer, Melanie Glazer, Wenchen Lin~~ and ~~Brian~~receiving E.three ~~Stewart~~written (the “Signing Stockholders”). The Voting Agreements require each Signing Stockholder to vote all of his or her shares (i) in favor of the adoption of the Merger Agreement and approval of the Merger, or in favor of any amendment to the Merger Agreement which makes the Merger Agreement more favorable to the Signing Stockholder, (ii) against approval of any proposal in opposition to the Merger or any other transaction contemplated by the Merger Agreement and (iii) against any competing proposals or competing transactions that would impede the Merger or result in a breach of the Merger Agreement. Pursuant to the Voting Agreements, each Signing Stockholder waives appraisal rights and provides an irrevocable proxy. The Voting Agreements do not limit or restrict the Signing Stockholder in his or her capacity as a director or officer from ~~acting~~other infinancial ~~such capacity or voting in such capacity in such person’s sole discretion on any matter.~~advisors,

The ~~Voting~~following ~~Agreements~~disclosure ~~and~~supplements ~~irrevocable proxies granted pursuant to~~ the ~~Voting~~disclosure ~~Agreements~~on ~~terminate~~page ~~upon~~23 ~~the~~of ~~earlier to occur: (i)~~ the ~~Merger~~Definitive ~~Agreement~~Proxy isStatement ~~terminated~~by inadding ~~accordance~~a ~~with~~new ~~its~~clause ~~terms,~~after ~~(ii)~~ the ~~effective~~first ~~time~~sentence ~~and (iii) the Company’s board~~ of ~~directors changes its recommendation that~~ the ~~Company’s~~sixth ~~stockholders~~paragraph ~~adopt~~on ~~the~~such ~~Merger Agreement.~~page:

~~Item~~that ~~8.01 Other~~were ~~Events~~in the medical device industry and would potentially have an interest in surgical products.

OnThe ~~December~~following ~~31,~~disclosure ~~2013,~~supplements the ~~Company~~disclosure ~~issued~~on apage ~~press~~23 ~~release~~of ~~announcing~~ the ~~execution~~Definitive ofProxy anStatement ~~Agreement~~by ~~and~~adding ~~Plan~~a ofnew ~~Merger,~~sentence ~~dated~~after ~~December 31, 2013 among~~ the ~~Company,~~last ~~Stryker~~sentence ~~and PS Merger Sub Inc.. The full text~~ of the ~~press~~sixth ~~release~~paragraph ison ~~attached~~such ~~hereto as Exhibit 99.1, and is incorporated herein by reference.~~page:

~~Forward~~The ~~Looking~~non-disclosure ~~Statements~~agreements signed by two of the potential acquirors, referenced as Company C and Company D below, contained standstill obligations that did not terminate automatically if Patient Safety entered into or publicly announced a business combination with a third party and that were still in effect at the time of filing.

~~Statements~~The infollowing ~~this~~disclosure ~~press~~supplements ~~release regarding~~ the ~~Company’s~~disclosure business that are not historical facts are "forward-looking statements" (within the meaning of Section 21E of the Securities Exchange Act of 1934) that involve risks and uncertainties. Forward-looking statements reflect management's current views with respect to future events and financial performance; however, you should not put undue reliance on ~~these~~page ~~statements. When~~23 used, the words "anticipates," "believes," "expects," "intends," "future," and other similar expressions, without limitation, identify forward-looking statements. These statements include those related to the expected benefits of the ~~Stryker~~Definitive ~~transaction~~Proxy ~~and~~Statement ~~the~~by ~~expected~~adding ~~closing~~a ~~date~~new ofclause ~~the~~at Stryker transaction. Forward-looking statements are not guarantees of future performance and are inherently subject to risks and uncertainties and other factors which could cause actual results to differ materially from the ~~forward-looking~~end ~~statements. These risks and uncertainties include such factors as: (1) the occurrence~~ of ~~any event, change or other circumstances that could give rise to~~ the ~~termination~~first ofsentence ~~the Stryker acquisition agreement, (2) the failure to obtain approval~~ of the ~~Company’s~~ninth ~~stockholders~~paragraph or the failure to satisfy any of the other closing conditions, (3) risks related to disruption of management's attention from the Company’s ongoing business operations due to the Stryker transaction and (4) the effect of the announcement of the Stryker transaction on ~~the~~such Company’s ability to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom the Company does business, or on the Company’s operating results and business generally. These risks and uncertainties also include but are not limited topage: the Company’s ability to implement in all hospitals within the larger hospitals organizations with which it has agreements, ability to implement in those hospitals with which it has scheduled implementations, the early stage of adoption of the Company’s Safety-Sponge® System and the need to expand adoption of the Safety-Sponge® System; the impact on future revenue and cash flows from the ordering patterns of the Company’s exclusive distributor Cardinal Health; the need for additional financing to support the Company’s business; the Company’s reliance on third-party manufacturers, some of whom are sole-source suppliers, and on its exclusive distributor; and any inability to successfully protect the Company’s intellectual property portfolio. In light of the risks and uncertainties, there can be no assurance that any forward-looking statement will in fact prove to be correct.

~~Forward-looking statements can be affected by many other factors~~, ~~including,~~expressing ~~those~~concerns ~~described~~over instrategic ~~the~~fit ~~"Business", "Management's Discussion~~ and ~~Analysis~~an ofinability Financial Condition and Results of Operations" and “Factors Affecting Future Results” sections of the Company’s Annual Report on Form 10-K for 2012, Quarterly Reports on Form 10-Q and other public filings. These documents are available online through the Security and Exchange Commission's (the “SEC”) website, www.sec.gov. Forward-looking statements are based on information presently available to ~~senior~~reach ~~management,~~a ~~and~~valuation ~~the~~that ~~Company~~would ~~has~~be ~~not~~acceptable ~~assumed any duty~~ to ~~update~~Patient ~~any forward-looking statements~~Safety.

The following disclosure supplements the disclosure on page 24 of the Definitive Proxy Statement by adding a new clause at the end of the first sentence of the third paragraph on such page:

, expressing an inability to reach a valuation that would be acceptable to Patient Safety.

The following disclosure supplements the disclosure on page 24 of the Definitive Proxy Statement by adding a new clause at the end of the first sentence of the seventh paragraph on such page:

, expressing an inability to reach a valuation that would be acceptable to Patient Safety.

~~Important~~The ~~Information~~section ~~for~~of ~~Investors~~the Definitive Proxy Statement entitled “The Merger—Opinion of Patient Safety’s Financial Advisor” is amended and ~~Shareholders~~supplemented as follows:

The ~~Company,~~following ~~Stryker,~~disclosure ~~their~~supplements ~~respective directors and certain of their executive officers may be considered participants in~~ the ~~solicitation~~disclosure ofon ~~proxies~~page in33 ~~connection with the proposed transaction. Information about the directors and executive officers~~ of the ~~Company~~Definitive isProxy ~~set~~Statement ~~forth~~by inreplacing ~~its Annual Report on Form 10-K for~~ the ~~year~~first ~~ended~~paragraph December 31, 2012, which was filed with the SEC on March 18, 2013, along with an amendment to its Annual Report on Form 10-K, which was filed with the SEC on April 30, 2013, its Quarterly Report on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013 and ~~September 30, 2013, which were filed with~~ the ~~SEC~~bullets onimmediately ~~May~~following ~~14,~~such ~~2013,~~first ~~August~~paragraph ~~12, 2013 and November 11, 2013 respectively, and certain of its Current Reports on Form 8-K, which were filed~~ with the ~~SEC~~following onparagraph ~~February 12, 2013, March 19, 2013, March 26, 2013, August 9, 2013, October 17, 2013, November 14, 2013, November 22, 2013~~ and ~~December 3, 2013. Information about~~ the ~~directors~~bullets ~~and~~below ~~executive officers of Stryker is set forth in its Annual Report~~ on ~~Form~~such 10-K for the year ended December 31, 2012, which was filed with the SEC on February 27, 2013, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013 and September 30, 2013 which were filed with the SEC on April 30, 2013, July 23, 2013 and October 23, 2013 respectively, its proxy statement for its 2013 annual meeting of stockholders, which was filed with the SEC on March 18, 2013, and certain of its Current Reports on Form 8-K, which were filed with the SEC on January 9, 2013, January 17, 2013, January 23, 2013, March 1, 2013, March 25, 2013, April 11, 2013, May 1, 2013, July 18, 2013, September 27, 2013, October 17, 2013, December 3, 2013, December 6, 2013 and December 17, 2013. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.page:

~~Additional~~Selected ~~Information~~Publicly Traded Companies Analysis. BofA Merrill Lynch reviewed publicly available financial and ~~Where~~stock market information for Patient Safety and the following 10 publicly traded companies in the medical device industry, six of which were deemed by BofA Merrill Lynch to ~~Find~~be Itsmall cap companies and four of which were deemed by BofA Merrill Lynch to be companies that specialize in sterilization, infection prevention and monitoring:

~~This~~Small ~~communication~~Cap is· ~~being~~Baxano ~~made~~Surgical, ~~in respect of the proposed transaction involving the Company and Stryker~~Inc. ~~The~~· ~~proposed~~LeMaitre ~~transaction~~Vascular, ~~will be submitted to the stockholders of the Company for their consideration~~Inc. In· ~~connection~~Merit ~~with~~Medical ~~the proposed transaction~~Systems, ~~the Company will prepare a proxy statement to be filed with the SEC~~Inc. · The ~~Company~~Spectranetics ~~and~~Corporation ~~Stryker~~· ~~plan~~Vascular toSolutions ~~file with the SEC other documents regarding the proposed transaction~~Inc. ~~STOCKHOLDERS~~· ~~ARE~~Zeltiq URGED TO READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive proxy statement will be mailed to Patient Safety TechnologiesAesthetics, Inc.’s ~~stockholders.~~Sterilization ~~You~~/ ~~may~~Infection ~~obtain~~Prevention ~~copies~~/ ofMonitoring ~~all~~· ~~documents~~STERIS ~~filed~~Corp. ~~with~~· ~~the~~Masimo ~~SEC~~Corporation ~~concerning~~· ~~the~~Cantel ~~proposed~~Medical ~~transaction, free of charge, at the SEC’s website at www~~Corp.~~sec.gov.~~ In· ~~addition,~~Natus ~~stockholders~~Medical ~~may obtain free copies of the documents filed with the SEC by sending a written request to PST’s Controller at Patient Safety Technologies,~~ Inc.~~, 15440 Laguna Canyon Road, Suite 150, Irvine, California 92618, or by calling the Controller at (949) 387-2277.~~

~~Item~~The ~~9.01~~following ~~Financial~~disclosure ~~Statements~~supplements ~~and~~the ~~Exhibits~~disclosure on page 33 of the Definitive Proxy Statement by adding two new sentences after the first sentence of the second to last paragraph on such page:

~~(d)~~BofA ~~Exhibits~~Merrill Lynch observed low, median, mean and high calendar year 2013 estimated revenue multiples for the small cap selected publicly traded companies of 1.82x, 2.81x, 3.72x and 6.82x, respectively, and low, median, mean and high calendar year 2014 estimated revenue multiples for such selected publicly traded companies of 1.09x, 2.54x, 3.18x and 5.76x, respectively. BofA Merrill Lynch observed low, median, mean and high calendar year 2013 estimated revenue multiples for the selected publicly traded companies specializing in sterilization, infection prevention and monitoring of 2.05x, 2.54x, 2.64x and 3.40x, respectively, and low, median, mean and high calendar year 2014 estimated revenue multiples for such selected publicly traded companies of 1.95x, 2.45x, 2.47x and 3.02x, respectively.

2.1		Agreement and Plan of Merger, dated as of December 31, 2013, by and between Stryker Corporation, PS Merger Sub Inc. and Patient Safety Technologies, Inc.
2.2		Form of Voting Agreement.
99.1		Press Release issued on December 31, 2013.

The following disclosure supplements the disclosure on page 33 of the Definitive Proxy Statement by adding a new clause after the second to last sentence of the second to last paragraph on such page:

and stock-based compensation of Patient Safety was treated as a cash expense.

The following disclosure supplements the disclosure on page 34 of the Definitive Proxy Statement by replacing the “:” at the end of the last sentence thereof with a “.” and adding a new sentence after the last sentence of the first paragraph on such page:

For purposes of its discounted cash flow analysis, BofA Merrill Lynch defined “standalone unlevered, after-tax free cash flows” as tax-effected earnings before interest and tax plus depreciation and amortization and less capital expenditures and changes in working capital:

The following disclosure supplements the disclosure on page 34 of the Definitive Proxy Statement by adding a new sentence after the first sentence of the second paragraph on such page:

BofA Merrill Lynch observed low, median, mean and high one-year forward revenue multiples for the selected transactions of 3.13x, 4.35x, 4.16x and 6.00x, respectively, and low, median, mean and high two-year forward revenue multiples for the selected transactions of 2.72x, 3.17x, 3.34x and 4.30x, respectively.

The following disclosure supplements the disclosure on page 34 of the Definitive Proxy Statement by adding a new clause after the second to last sentence of the second paragraph on such page:

and stock-based compensation of Patient Safety was treated as a cash expense.

The following disclosure supplements the disclosure on page 34 of the Definitive Proxy Statement by adding a new phrase after the word “using” and before the phrase “discount rates” in the fifth sentence of the last paragraph on such page:

end of period discounting and

The following disclosure supplements the disclosure on page 34 of the Definitive Proxy Statement by adding a new clause at the end of the fifth sentence of the last paragraph on such page:

, taking into account certain financial metrics, including levered and unlevered beta, tax rates and current yields for U.S. treasury notes based on publicly available sources.

The following disclosure supplements the disclosure on page 36 of the Definitive Proxy Statement by adding a new paragraph after the third paragraph on such page:

BofA Merrill Lynch and its affiliates have not provided any material investment banking, commercial banking or other financial services to Patient Safety in the past two years.

The Definitive Proxy Statement is amended and supplemented by adding the following section entitled “The Merger—Projected Financial Information” onto page 36:

Projected Financial Information

Patient Safety does not as a matter of course make public projections as to future performance or earnings and is especially wary of making projections for extended periods due to the unpredictability of the underlying assumptions and estimates. However, in connection with Patient Safety’s regular internal planning process and with the Merger, Patient Safety’s management prepared internal financial projections based on a variety of assumptions and provided a preliminary version of the projections to its financial advisor, BofA Merrill Lynch, and the Patient Safety board. In December 2013, Patient Safety provided to BofA Merrill Lynch and the Patient Safety board updated financial projections that reflected a number of revised assumptions and estimates, including the impact of actual results during the months subsequent to the preliminary projections, increased regulatory concerns and changes in Patient Safety’s installed and expected future customer base. We have included a summary of the updated projections below to give our stockholders access to certain nonpublic information provided to our financial advisor and the Patient Safety board for purposes of considering and evaluating the Merger, including the delivery of the opinion delivered by BofA Merrill Lynch described under “The Merger – Opinion of Patient Safety’s Financial Advisor.” The inclusion of the projections should not be regarded as an indication that the Patient Safety board, Patient Safety, BofA Merrill Lynch or any other recipient of this information considered, or now considers, them to be an assurance of the achievement of future results. In addition, the projections have not been updated further or revised to reflect information or results after the date the projections were prepared or as of date of this proxy statement.

Patient Safety advised the recipients of the projections that its internal financial forecasts upon which the projections were based are subjective in many respects. The projections reflect numerous assumptions with respect to company performance, industry performance, general business, economic, market and financial conditions and other matters, many of which are difficult to predict, subject to significant economic and competitive uncertainties and beyond Patient Safety’s control. As a result, there can be no assurance that the projections will be realized or that actual results will not be significantly higher or lower than projected.

The projections were prepared for internal use and to assist Patient Safety’s financial advisor with its due diligence investigations of Patient Safety. The projections were not prepared with a view toward public disclosure or toward compliance with United States generally accepted accounting principles (“GAAP”), published guidelines of the SEC or the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information. The prospective financial information included in this proxy statement has been prepared by, and is the responsibility of, Patient Safety’s management. Squar, Milner, Peterson, Miranda & Williamson, LLP (“SMPMW”), Patient Safety’s independent registered public accounting firm, has not examined, compiled or performed any procedures with respect to the accompanying prospective financial information, and accordingly, SMPMW does not express an opinion or any other form of assurance with respect thereto. The SMPMW report incorporated by reference in this proxy statement relates to Patient Safety’s historical financial information. It does not extend to the prospective financial information and should not be read to do so.

Projections of this type are based on estimates and assumptions that are inherently subject to factors such as company performance, industry performance, general business, economic, regulatory, market and financial conditions, as well as changes to the business, financial condition or results of operations of Patient Safety, including the factors described under “Cautionary Statement Concerning Forward-Looking Statements,” which factors may cause the projections or the underlying assumptions to be inaccurate. Since the projections cover multiple years, such information by its nature becomes less reliable with each successive year. The projections do not take into account any circumstances or events occurring after the date they were prepared.

The following is a summary of the projections:

Summary of Projections

(dollars in millions, except percentage data)

	Fiscal Year Ended December 31,
		2014E			2015E			2016E			2017E		Normalized
Revenue	$	32.6		$	44.8		$	61.7		$	87.2		$	87.2
Revenue Growth Rate		47.0	%		37.4	%		37.8	%		41.3	%		-
EBITDA(1)	$	4.6		$	11.3		$	19.5		$	33.1		$	33.1
Margin		14.2	%		25.1	%		31.5	%		37.9	%		37.9	%
EBIT(2)	$	3.1		$	9.8		$	18.4		$	31.8		$	31.1
Margin		9.4	%		21.8	%		29.8	%		36.4	%		35.6	%

(1)	We define EBITDA as earnings before interest, tax, depreciation and amortization.

(2)	We define EBIT as earnings before interest and tax.

Forward Looking Statements

Statements in this filing regarding the Company’s business that are not historical facts are "forward-looking statements" (within the meaning of Section 21E of the Securities Exchange Act of 1934) that involve risks and uncertainties. Forward-looking statements reflect the Company’s management's current views with respect to future events and financial performance; however, you should not put undue reliance on these statements. When used, the words "anticipates," "believes," "expects," "intends," "future," and other similar expressions, without limitation, identify forward-looking statements. These statements include those related to the expected benefits of the Stryker transaction and the expected closing date of the Stryker transaction. Forward-looking statements are not guarantees of future performance and are inherently subject to risks and uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. These risks and uncertainties include such factors as: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Stryker acquisition agreement, (2) the failure to obtain approval of the Company’s stockholders or the failure to satisfy any of the other closing conditions, (3) risks related to disruption of management's attention from the Company’s ongoing business operations due to the Stryker transaction and (4) the effect of the announcement of the Stryker transaction on the Company’s ability to retain and hire key personnel and maintain relationships with the Company’s customers, suppliers and others with whom the Company does business, or on the Company’s operating results and business generally. These risks and uncertainties also include but are not limited to: the Company’s ability to implement in all hospitals within the larger hospitals organizations with which the Company has agreements, the Company’s ability to implement in those hospitals with which the Company has scheduled implementations, the early stage of adoption of the Company’s Safety-Sponge® System and the need to expand adoption of the Company’s Safety-Sponge® System; the impact on the Company’s future revenue and cash flows from the ordering patterns of the Company’s exclusive distributor Cardinal Health; the Company’s need for additional financing to support the Company’s business; the Company’s reliance on third-party manufacturers, some of whom are sole-source suppliers, and on the Company’s exclusive distributor; and any inability to successfully protect the Company’s intellectual property portfolio. In light of the risks and uncertainties, there can be no assurance that any forward-looking statement will in fact prove to be correct.

Forward-looking statements can be affected by many other factors, including, those described in the "Business”, "Management's Discussion and Analysis of Financial Condition and Results of Operations” and “Factors Affecting Future Results” sections of the Company’s Annual Report on Form 10-K for 2012, the Company’s Quarterly Reports on Form 10-Q and in the Company’s other public filings. These documents are available online through the SEC’s website, www.sec.gov. Forward-looking statements are based on information presently available to senior management, and the Company has not assumed any duty to update any forward-looking statements.

Additional Information and Where to Find It

This communication is being made in respect of the proposed transaction involving the Company and Stryker. The proposed transaction will be submitted to the stockholders of the Company for their consideration. In connection with the proposed transaction, the Company prepared a definitive proxy statement which was filed with the SEC on February 25, 2014. The Company and Stryker plan to file with the SEC other documents regarding the proposed transaction. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive proxy statement will be mailed to Patient Safety Technologies, Inc.’s stockholders. You may obtain copies of all documents filed with the SEC concerning the proposed transaction, free of charge, at the SEC’s website at www.sec.gov. In addition, stockholders may obtain free copies of the documents filed with the SEC by Patient Safety Technologies, Inc. by going to Patient Safety Technologies, Inc.’s Investor Relations website page by clicking the “Investors” link at www.surgicountmedical.com or by sending a written request to Patient Safety Technologies, Inc.’s Secretary at Patient Safety Technologies, Inc., 15440 Laguna Canyon Road, Suite 150, Irvine, California 92618, or by calling the Secretary at (949) 387-2277.

The Company and its directors, executive officers and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s shareholders with respect to the proposed acquisition of the Company by Stryker. Security holders may obtain information regarding the names, affiliations and interests of such individuals in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as amended. Additional information regarding the interests of such individuals in the proposed acquisition of the Company by Stryker is included in the Definitive Proxy Statement. These documents may be obtained free of charge from the SEC’s website at www.sec.gov and the Company’s website at http://www.surgicountmedical.com/.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this ~~report~~filing to be signed on its behalf by the undersigned hereunto duly authorized.

	PATIENT SAFETY TECHNOLOGIES, INC.
Date: December 31, 2013	By:	/s/ David C. Dreyer
Date: March 11, 2014	By:	/s/ David C. Dreyer
		David C. Dreyer, Executive Vice President,
		Chief Financial Officer, and Secretary

EXHIBIT INDEX

Exhibit Number		Description of Exhibits
2.1		Agreement and Plan of Merger, dated as of December 31, 2013, by and between Stryker Corporation, PS Merger Sub Inc. and Patient Safety Technologies, Inc.
2.2		Form of Voting Agreement.
99.1		Press Release issued on December 31, 2013.

Filing Compare · Patient Safety Technologies, Inc